Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
Head and Neck Cancer, Lung Cancer
About this trial
This is an interventional screening trial for Head and Neck Cancer focused on measuring stage I non-small cell lung cancer, stage II non-small cell lung cancer, stage III non-small cell lung cancer, limited stage small cell lung cancer, stage I nasopharyngeal cancer, stage II nasopharyngeal cancer, stage III nasopharyngeal cancer, stage I lip and oral cavity cancer, stage II lip and oral cavity cancer, stage III lip and oral cavity cancer, stage I hypopharyngeal cancer, stage II hypopharyngeal cancer, stage III hypopharyngeal cancer, stage I laryngeal cancer, stage II laryngeal cancer, stage III laryngeal cancer, stage I paranasal sinus and nasal cavity cancer, stage II paranasal sinus and nasal cavity cancer, stage III paranasal sinus and nasal cavity cancer, stage I oropharyngeal cancer, stage II oropharyngeal cancer, stage III oropharyngeal cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: The following diagnoses are eligible: Known or suspected bronchogenic carcinoma scheduled for bronchoscopy as part of standard diagnostic or staging work-up Completely resected stage I/II non-small cell lung cancer with no evidence of metastasis Stage III non-small cell lung cancer with no evidence of disease for at least 2 years following treatment Small cell lung cancer with no evidence of disease for at least 2 years following treatment Completely resected head and neck cancer with no evidence of metastasis Ability to produce sputum samples required PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC 2,000-20,000 Platelets at least 50,000 Hepatic: Not specified Renal: Not specified Cardiovascular: No uncontrolled hypertension (i.e., systolic pressure greater than 200 mm Hg or diastolic pressure greater than 120 mm Hg) No unstable angina Other: No bleeding disorder No allergic reaction to topical lidocaine No pregnant women PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy At least 18 months since ionizing radiotherapy to the chest Surgery See Disease Characteristics Other At least 1 month since yttrium-aluminum-garnet (YAG) laser therapy to the lung At least 3 months since fluorescent photosensitizing drugs (e.g., Photofrin)
Sites / Locations
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support